Biophan to Present at Stephens Inc. 2005 Nanotechnology Investors Conference April 5 - 6 in California; CEO Michael Weiner to Outline Company's Leading Nanotechnology Solutions in Multi-Billion-Dollar Biomedical Sectors.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, will present an overview of its proprietary innovations in the development of nanotechnology solutions for multi-billion-dollar healthcare markets as a featured company at the 2005 Stephens Inc. Nanotechnology Investors Conference, to be held April 5 - 6 at the Ritz-Carlton hotel, in Pasadena, CA.

"Biophan's successful research and development program has already yielded a uniquely broad patent thicket in a number of advanced nanotechnology solutions in next-generation medical device and healthcare markets," said Michael Weiner, Biophan CEO. "Our intellectual property portfolio will enable us to offer our strategic partners competitive advantage based on important product advantages, backed up by enforceable patents, in important biomedical sectors that are transforming healthcare, such as enhanced Magnetic Resonance Imaging, active drug-delivery systems controlled by non-invasive fields, and biomedical battery technology. Four of our six key platform technologies are based on patented advances in nanotechnology, hence we are very pleased to be presenting at the Stephens Conference."

Biophan recently announced new patent issuances that expand its intellectual property portfolio to a total of 114 U.S. patents, licenses, or applications. This includes 34 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 72 pending applications.

Mr. Weiner is scheduled to start his presentation at the Nanotechnology Investors Conference at 8:30 a.m. on April 6. The two-day conference will bring together leading nanotechnology companies and a range of guest speakers with a mix of scientific, investment, and industry experience. Delivering the keynote address is Dr. Michael L. Roukes, Founding Director of the Kavli Nanoscience Institute at the California Institute of Technology (Caltech).

About Stephens Inc.

Stephens Inc. is a full-service, privately-owned Investment Bank headquartered in Little Rock, Arkansas, with offices across the country in key markets, as well as abroad in London. Founded in 1933, Stephens Inc. provides a broad range of investment and research services. More information about the 2005 Stephens Inc. Nanotechnology Investors Conference can be found at www.stephens.com/research/conference-information.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 34 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.